{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:21:53Z","timestamp":1790990513116,"version":"4.1.0"},"reference-count":58,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,4,19]],"date-time":"2020-04-19T00:00:00Z","timestamp":1587254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2012\/13032-5"],"award-info":[{"award-number":["2012\/13032-5"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2014\/18102-7"],"award-info":[{"award-number":["2014\/18102-7"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"name":"French Government\u2019s Investissement d\u2019Avenir program, Laboratoire d\u2019Excellence Integrative Biology of Emerging Infectious Diseases","award":["ANR-10-LABX-62-IBEID"],"award-info":[{"award-number":["ANR-10-LABX-62-IBEID"]}]},{"name":"National Institute of Science and Technology for Vaccines","award":["465293\/2014-0"],"award-info":[{"award-number":["465293\/2014-0"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Plasmodium vivax is the most common species of human malaria parasite found outside Africa, with high endemicity in Asia, Central and South America, and Oceania. Although Plasmodium falciparum causes the majority of deaths, P. vivax can lead to severe malaria and result in significant morbidity and mortality. The development of a protective vaccine will be a major step toward malaria elimination. Recently, a formulation containing the three allelic variants of the P. vivax circumsporozoite protein (PvCSP\u2014All epitopes) showed partial protection in mice after a challenge with the hybrid Plasmodium berghei (Pb) sporozoite, in which the PbCSP central repeats were replaced by the VK210 PvCSP repeats (Pb\/Pv sporozoite). In the present study, the chimeric PvCSP allelic variants (VK210, VK247, and P. vivax-like) were fused with the mumps virus nucleocapsid protein in the absence (NLP-CSPR) or presence of the conserved C-terminal (CT) domain of PvCSP (NLP-CSPCT). To elicit stronger humoral and cellular responses, Pichia pastoris yeast was used to assemble them as nucleocapsid-like particles (NLPs). Mice were immunized with each recombinant protein adjuvanted with Poly (I:C) and presented a high frequency of antigen-specific antibody-secreting cells (ASCs) on days 5 and 30, respectively, in the spleen and bone marrow. Moreover, high IgG titers against all PvCSP variants were detected in the sera. Later, these immunized mice with NLP-CSPCT were challenged with Pb\/Pv sporozoites. Sterile protection was observed in 30% of the challenged mice. Therefore, this vaccine formulation use has the potential to be a good candidate for the development of a universal vaccine against P. vivax malaria.<\/jats:p>","DOI":"10.3390\/vaccines8020190","type":"journal-article","created":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T04:49:38Z","timestamp":1587444578000},"page":"190","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Protective Malaria Vaccine in Mice Based on the Plasmodium vivax Circumsporozoite Protein Fused with the Mumps Nucleocapsid Protein"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4402-9131","authenticated-orcid":false,"given":"Rodolfo F.","family":"Marques","sequence":"first","affiliation":[{"name":"Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of S\u00e3o Paulo, S\u00e3o Paulo 05508-000 SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba Marina","family":"Gimenez","sequence":"additional","affiliation":[{"name":"Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of S\u00e3o Paulo, S\u00e3o Paulo 05508-000 SP, Brazil"},{"name":"Center of Cellular and Molecular Therapy, Federal University of S\u00e3o Paulo, S\u00e3o Paulo 04044-010 SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Aliprandini","sequence":"additional","affiliation":[{"name":"Unit of Malaria Infection &amp; Immunity, Institut Pasteur, 75015 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9094-4050","authenticated-orcid":false,"given":"Janaina T.","family":"Novais","sequence":"additional","affiliation":[{"name":"Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of S\u00e3o Paulo, S\u00e3o Paulo 05508-000 SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego P.","family":"Cury","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Institute of Biomedical Sciences, University of S\u00e3o Paulo, S\u00e3o Paulo 05508-000 SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ii-Sei","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Anatomy, Institute of Biomedical Sciences, University of S\u00e3o Paulo, S\u00e3o Paulo 05508-000 SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana R.","family":"Dominguez","sequence":"additional","affiliation":[{"name":"Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of S\u00e3o Paulo, S\u00e3o Paulo 05508-000 SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8333-2884","authenticated-orcid":false,"given":"Eduardo L. V.","family":"Silveira","sequence":"additional","affiliation":[{"name":"Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of S\u00e3o Paulo, S\u00e3o Paulo 05508-000 SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogerio","family":"Amino","sequence":"additional","affiliation":[{"name":"Unit of Malaria Infection &amp; Immunity, Institut Pasteur, 75015 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3336-6856","authenticated-orcid":false,"given":"Irene S.","family":"Soares","sequence":"additional","affiliation":[{"name":"Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of S\u00e3o Paulo, S\u00e3o Paulo 05508-000 SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,4,19]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2018). World Malaria Report 2018, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/S1473-3099(14)70855-2","article-title":"Global extent of chloroquine-resistant Plasmodium vivax: A systematic review and meta-analysis","volume":"14","author":"Price","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Villamil-G\u00f3mez, W.E., Eyes-Escalante, M., and Franco-Paredes, C. (2016). Severe and Complicated Malaria Due to Plasmodium Vivax. Current Topics in Malaria, InTech.","DOI":"10.5772\/64974"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"malERA (2011). Consultative Group on Vaccines. A research agenda for malaria eradication: Vaccines. PLoS Med., 8.","DOI":"10.1371\/journal.pmed.1000398"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijpara.2016.09.006","article-title":"Plasmodium vivax vaccine research\u2014we\u2019ve only just begun","volume":"47","author":"Tham","year":"2017","journal-title":"Int. J. Parasitol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1056\/NEJMoa1207564","article-title":"Four-year efficacy of RTS,S\/AS01E and its interaction with malaria exposure","volume":"368","author":"Olotu","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: Final results of a phase 3, individually randomised, controlled trial","volume":"386","author":"RTS","year":"2015","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1038\/s41467-019-10195-z","article-title":"Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S\/AS01E malaria vaccine efficacy","volume":"10","author":"Dobano","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1126\/science.2414847","article-title":"Circumsporozoite protein of Plasmodium vivax: Gene cloning and characterization of the immunodominant epitope","volume":"230","author":"Arnot","year":"1985","journal-title":"Science"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1126\/science.2672336","article-title":"Circumsporozoite protein heterogeneity in the human malaria parasite Plasmodium vivax","volume":"245","author":"Rosenberg","year":"1989","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/0140-6736(93)90559-Y","article-title":"Identification of Plasmodium vivax-like human malaria parasite","volume":"341","author":"Qari","year":"1993","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1590\/S0074-02762007000300002","article-title":"The genetic diversity of Plasmodium vivax\u2014A review","volume":"102","author":"Machado","year":"2007","journal-title":"Mem Inst. Oswaldo Cruz"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1475-2875-12-16","article-title":"Genetic diversity of Plasmodium vivax clinical isolates from southern Pakistan using pvcsp and pvmsp1 genetic markers","volume":"12","author":"Raza","year":"2013","journal-title":"Malaria J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40249-018-0428-1","article-title":"Evaluating seroprevalence to circumsporozoite protein to estimate exposure to three species of Plasmodium in the Brazilian Amazon","volume":"7","author":"Pereira","year":"2018","journal-title":"Infect. Dis. Poverty"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1590\/S0074-02762007005000041","article-title":"Prevalence and level of antibodies to the circumsporozoite protein of human malaria parasites in five states of the Amazon region of Brazil","volume":"102","author":"Arruda","year":"2007","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","article-title":"Immunogenicity of the RTS,S\/AS01 malaria vaccine and implications for duration of vaccine efficacy: Secondary analysis of data from a phase 3 randomised controlled trial","volume":"15","author":"White","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"46482","DOI":"10.1038\/srep46482","article-title":"Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models","volume":"7","author":"Salman","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Atcheson, E., Bauza, K., Salman, A.M., Alves, E., Blight, J., Viveros-Sandoval, M.E., Janse, C.J., Khan, S.M., Hill, A.V.S., and Reyes-Sandoval, A. (2018). Tailoring a Plasmodium vivax Vaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors. Infect. Immun., 86.","DOI":"10.1128\/IAI.00114-18"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7489","DOI":"10.1016\/j.vaccine.2015.09.060","article-title":"Development of vaccines for Plasmodium vivax malaria","volume":"33","author":"Mueller","year":"2015","journal-title":"Vaccine"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Bennett, J.W., Yadava, A., Tosh, D., Sattabongkot, J., Komisar, J., Ware, L.A., McCarthy, W.F., Cowden, J.J., Regules, J., and Spring, M.D. (2016). Phase 1\/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001\/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy. PLoS Negl. Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004423"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1128\/IAI.01410-13","article-title":"Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of Plasmodium vivax in rodents","volume":"82","author":"Teixeira","year":"2014","journal-title":"Infect. Immun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.3389\/fimmu.2017.01275","article-title":"Vaccine Containing the Three Allelic Variants of the Plasmodium vivax Circumsporozoite Antigen Induces Protection in Mice after Challenge with a Transgenic Rodent Malaria Parasite","volume":"8","author":"Gimenez","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coviro.2016.03.001","article-title":"Engineering virus-like particles as vaccine platforms","volume":"18","author":"Frietze","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.nbt.2017.07.010","article-title":"Production of virus-like particles for vaccines","volume":"39","author":"Fuenmayor","year":"2017","journal-title":"N Biotechnol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.clim.2017.08.004","article-title":"Adjuvant formulations for virus-like particle (VLP) based vaccines","volume":"183","author":"Cimica","year":"2017","journal-title":"Clin. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s12250-016-3756-y","article-title":"Virus like particle-based vaccines against emerging infectious disease viruses","volume":"31","author":"Liu","year":"2016","journal-title":"Virol. Sin."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.vetimm.2012.04.026","article-title":"Virus-like particles: The new frontier of vaccines for animal viral infections","volume":"148","author":"Crisci","year":"2012","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.29245\/2578-3009\/2018\/2.1118","article-title":"Advances and Challenges in Enveloped Virus-like Particle (VLP)-Based Vaccines","volume":"2","author":"Dai","year":"2018","journal-title":"J. Immunol. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1084\/jem.20072681","article-title":"The failed HIV Merck vaccine study: A step back or a launching point for future vaccine development?","volume":"205","author":"Sekaly","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-1656(03)00068-3","article-title":"Synthesis of mumps virus nucleocapsid protein in yeast Pichia pastoris","volume":"103","author":"Slibinskas","year":"2003","journal-title":"J. Biotechnol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s10096-011-1216-z","article-title":"Assessment of mumps virus-specific antibodies by different serological assays: Which test correlates best with mumps immunity?","volume":"30","author":"Allwinn","year":"2011","journal-title":"Eur J. Clin. Microbiol Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Jacob, D., Ruffie, C., Dubois, M., Combredet, C., Amino, R., Formaglio, P., Gorgette, O., Pehau-Arnaudet, G., Guery, C., and Puijalon, O. (2014). Whole Pichia pastoris yeast expressing measles virus nucleoprotein as a production and delivery system to multimerize Plasmodium antigens. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0086658"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1128\/CVI.00312-13","article-title":"Immunogenicity of recombinant proteins consisting of Plasmodium vivax circumsporozoite protein allelic variant-derived epitopes fused with Salmonella enterica Serovar Typhimurium flagellin","volume":"20","author":"Leal","year":"2013","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1016\/j.vaccine.2017.03.023","article-title":"Generation, characterization and immunogenicity of a novel chimeric recombinant protein based on Plasmodium vivax AMA-1 and MSP119","volume":"35","author":"Rocha","year":"2017","journal-title":"Vaccine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"113554","DOI":"10.1016\/j.envpol.2019.113554","article-title":"Hydroquinone exposure alters the morphology of lymphoid organs in vaccinated C57Bl\/6 mice","volume":"257","author":"Fabris","year":"2020","journal-title":"Environ. Pollut"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1128\/IAI.00461-13","article-title":"Development of a chimeric Plasmodium berghei strain expressing the repeat region of the P. vivax circumsporozoite protein for in vivo evaluation of vaccine efficacy","volume":"81","author":"Espinosa","year":"2013","journal-title":"Infect. Immun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/s41564-018-0254-z","article-title":"Cytotoxic anti-circumsporozoite antibodies target malaria sporozoites in the host skin","volume":"3","author":"Aliprandini","year":"2018","journal-title":"Nat. Microbiol."},{"key":"ref_38","first-page":"1459394","article-title":"Adjuvants: Classification, Modus Operandi, and Licensing","volume":"2016","author":"Lunardelli","year":"2016","journal-title":"J. Immunol. Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jim.2014.11.003","article-title":"Vaccine-induced plasmablast responses in rhesus macaques: Phenotypic characterization and a source for generating antigen-specific monoclonal antibodies","volume":"416","author":"Silveira","year":"2015","journal-title":"J. Immunol. Methods"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Kasturi, S.P., Kozlowski, P.A., Nakaya, H.I., Burger, M.C., Russo, P., Pham, M., Kovalenkov, Y., Silveira, E.L.V., Havenar-Daughton, C., and Burton, S.L. (2017). Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5alpha Restrictive Macaques. J. Virol., 91.","DOI":"10.1128\/JVI.01844-16"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/s41598-017-19063-6","article-title":"Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb\/Pv sporozoite challenge","volume":"8","author":"Gimenez","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major findings and recent advances in virus-like particle (VLP)-based vaccines","volume":"34","author":"Mohsen","year":"2017","journal-title":"Semin. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"8630","DOI":"10.1128\/JVI.78.16.8630-8640.2004","article-title":"Characterization of nucleocapsid binding by the measles virus and mumps virus phosphoproteins","volume":"78","author":"Kingston","year":"2004","journal-title":"J. Virol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/21655979.2016.1191707","article-title":"Recent advances in the production of recombinant subunit vaccines in Pichia pastoris","volume":"7","author":"Wang","year":"2016","journal-title":"Bioengineered"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.3389\/fmicb.2017.02644","article-title":"Pichia pastoris-Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo","volume":"8","author":"Shukla","year":"2017","journal-title":"Front. Microbiol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Saraswat, S., Athmaram, T.N., Parida, M., Agarwal, A., Saha, A., and Dash, P.K. (2016). Expression and Characterization of Yeast Derived Chikungunya Virus Like Particles (CHIK-VLPs) and Its Evaluation as a Potential Vaccine Candidate. PLoS Negl. Trop. Dis., 10.","DOI":"10.1371\/journal.pntd.0004782"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"6216","DOI":"10.1016\/j.vaccine.2013.10.041","article-title":"Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques","volume":"31","author":"Vanloubbeeck","year":"2013","journal-title":"Vaccine"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cytogfr.2011.02.001","article-title":"Toll-like receptor, RIG-I-like receptors and the NLRP3 inflammasome: Key modulators of innate immune responses to double-stranded RNA viruses","volume":"22","author":"Yu","year":"2011","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1126\/science.1087262","article-title":"Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway","volume":"301","author":"Yamamoto","year":"2003","journal-title":"Science"},{"key":"ref_50","first-page":"671","article-title":"CD4 T-cell subsets in malaria: TH1\/TH2 revisited","volume":"5","author":"Langhorne","year":"2014","journal-title":"Front. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Schwenk, R., DeBot, M., Porter, M., Nikki, J., Rein, L., Spaccapelo, R., Crisanti, A., Wightman, P.D., Ockenhouse, C.F., and Dutta, S. (2014). IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0111020"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/ni.3680","article-title":"Defining B cell immunodominance to viruses","volume":"18","author":"Angeletti","year":"2017","journal-title":"Nat. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"13474","DOI":"10.1073\/pnas.1816300116","article-title":"Outflanking immunodominance to target subdominant broadly neutralizing epitopes","volume":"116","author":"Angeletti","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Yadava, A., and Waters, N.C. (2017). Rationale for Further Development of a Vaccine Based on the Circumsporozoite Protein of Plasmodium vivax. PLoS Negl. Trop. Dis., 11.","DOI":"10.1371\/journal.pntd.0005164"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.4512","article-title":"A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite","volume":"24","author":"Kisalu","year":"2018","journal-title":"Nat. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.chom.2019.01.010","article-title":"Persistent Antibody Clonotypes Dominate the Serum Response to Influenza over Multiple Years and Repeated Vaccinations","volume":"25","author":"Lee","year":"2019","journal-title":"Cell Host Microbe"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.pt.2016.12.011","article-title":"Theoretical Implications of a Pre-Erythrocytic Plasmodium vivax Vaccine for Preventing Relapses","volume":"33","author":"White","year":"2017","journal-title":"Trends Parasitol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0035-9203(90)90258-G","article-title":"An estimation of the number of malaria sporozoites ejected by a feeding mosquito","volume":"84","author":"Rosenberg","year":"1990","journal-title":"Trans. R Soc. Trop. Med. Hyg."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/2\/190\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:09:03Z","timestamp":1760364543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/8\/2\/190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,19]]},"references-count":58,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["vaccines8020190"],"URL":"https:\/\/doi.org\/10.3390\/vaccines8020190","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,19]]}}}